Xencor Licenses Fc Antibody Engineering IP to Merck MONROVIA, Calif., July 2, 2013 – Xencor, Inc. announced today that that it has entered into a technology license and option agreement to provide Merck, known as MSD outside the United States and Canada, access to one of Xencor's Fc

Xencor Licenses Caltech Technology (BW Healthwire)–November 30, 1998—Xencor Inc. announced the execution of a worldwide, exclusive licensing agreement with the California Institute of Technology (Caltech) for key enabling technology including know-how and patents for Protein Design Automation

Xencor Licenses Antibody Optimization Technology Monrovia, Calif. – November 30, 2009 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology

Advancing XmAb5871 in two indications with high unmet need and strong rationale for B-cell inhibitionNovel trial design for SLE intended to detect statistically significant treatment effect after 6 months of therapy

Xencor Initiates Phase I Clinical Trial with XmAb2513 in Lymphoma Monrovia, Calif. – February 11, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, has initiated a Phase I clinical trial with its lead product candidate XmAb™2513 in patients with Hodgkin lymphoma (HL) and

Xencor Initiates Phase 1b/2a Trial of XmAbR5871 for Autoimmune Disease MONROVIA, Calif., February 13, 2013—Xencor, Inc. today announced that the first patient has been dosed in a Phase 1b/2a clinical trial of XmAb®5871 in patients with moderate to severe rheumatoid arthritis.

MONROVIA, Calif. , Sept. 15, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the first patient has been

Xencor Initiates Phase 1 Study of XmAb ® 5871 Therapeutic Antibody For the Treatment of Autoimmune Diseases; Dual-Targeted Antibody Aims to Treat Lupus and Rheumatoid Arthritis by Suppressing Autoimmune Response Monrovia, Calif. – Oct. 21, 2011 – Xencor, Inc., a company using its

MONROVIA, Calif. , May 28, 2014 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the first subject has been

PASADENA, Calif. --(BUSINESS WIRE)--Apr. 17, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented new preclinical data generated from engineered CD28